Comparing Biologics in CRSwNP Care

In this episode of EUFOREA TV Breaking News, we will discuss the fundamentals of Rhinosinusitis or CRS, which is a symptomatic chronic inflammatory syndrome of the nose and paranasal sinuses and affects around 6% to 12% of patients in the West. Approximately 20% of these cases account for chronic rhinosinusitis with nasal polyps. CRSwNP is often difficult to treat for the arrival of new treatments, but biologics may be a promising therapy for some patients.

Our guests, Prof. Wytske Fokkens, Professor of Otorhinolaryngology at the Academic medical centre in Amsterdam and Secretary general of ERS, and Prof. Anju Tripathi Peters, Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, USA, explain more about the trials and discuss which biologicals may be suitable for certain patients with different symptoms and compare different biologicals in CRSwNP while highlighting the concept of personalized medicine and tailored therapy.

⚖️ Promising therapies for patients with CRSwNP: Comparing Biologics ‘We are doing very much precision medicine and that’s one of the reasons we think that these drugs work, and they really do help patients.’

Indirect treatment Comparison of Biologics in CRSwNP

State-of-the-art overview on biological treatment for CRSwNP